FDA announce that vaccinations with JNJ 78436735 for COVID-19 can restart – Johnson & Johnson

Johnson & Johnson announced that vaccinations with JNJ 78436735, the Company’s COVID-19 single-shot vaccine, will resume for all adults aged 18 years and older in the U.S., under Emergency Use Authorization (EUA), following a decision from the United States Centers for Disease Control (CDC) and Food and Drug Administration (FDA).

The decision was based on a recommendation from the U.S. CDC Advisory Committee on Immunization Practices (ACIP), which followed a rigorous evaluation of data relating to a very rare adverse event involving blood clots in combination with low platelet counts (thrombosis with thrombocytopenia) observed within approximately one to two weeks following vaccination.